-
Article
Open AccessSecond breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry
Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent...
-
Article
Open AccessDevelopment and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in p...
-
Article
Open AccessBCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression
The molecular processes by which some human ductal carcinoma in situ (DCIS) lesions advance to the more aggressive form, while others remain indolent, are largely unknown. Experiments utilizing a patient-deriv...
-
Article
Open AccessMenstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer
The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ brea...
-
Article
Open AccessTen-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life cli...
-
Article
Open AccessESR1 mutations in metastatic lobular breast cancer patients
Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast cancer (IDC), accounts for up to 15% of all invasive cases and generally express t...
-
Article
Open AccessMolecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy
For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describin...
-
Article
Open AccessClinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive brea...
-
Article
Open AccessClinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
The 21-gene Recurrence Score® (RS) assay is a validated prognostic/predictive tool in ER + early-stage breast cancer. However, clinical outcome data from prospective studies in RS ≥ 11 patients are lacking, as...
-
Article
Open AccessAndrogen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
Increased rates of locoregional recurrence have been observed in triple-negative breast cancer despite chemotherapy and radiation therapy. Thus, approaches that combine therapies for radiosensitization in trip...